EDX Medical Group plc (AQSE:EDX), a developer of innovative digital diagnostic products and services for personalised treatment of cancer, heart disease and infectious diseases, has announced it has entered into a collaborative agreement with Thermo Fisher Scientific EMEA Ltd. the world leader in serving science and supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services.
The collaboration agreement will enable EDX Medical and Thermo Fisher to jointly develop and potentially commercialise a number of proprietary qPCR assays – including novel and innovative cancer diagnostic solutions. The multi project collaboration will harness Thermo Fisher’s powerful technologies and information translation systems to deliver a number of advanced testing solutions in development at EDX or licensed from partners, including a proprietary assay to enable personalised radiotherapy and a novel chemotherapy toxicity assay focusing on serious adverse events.
